Claritev Corp (CTEV) News & EventsCTEVNews & EventsClaritev Corp

Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations

Reports Q2 revenue $257.48M, consensus $244.81M. "Claritev once again demonstrated the strength of our vision and strategy in the second quarter of 2026, delivering financial results above expectations with solid execution across the company. We are one year into a transformation program that has seen our company operate with greater clarity, alignment, and focus. This transformation is most notably highlighted by a broader portfolio of solutions, expanded vertical sales markets, heightened focus on AI as both an operational and innovation lever, and a company-wide focus on execution that is building a foundation for long term, sustainable, and ultimately faster growth," said Travis Dalton, Chairman, CEO and President of Claritev.

Company Raises FY26 Adjusted EBITDA Outlook to $620M

Consensus $993.39M. Raises FY26 adjusted EBITDA view to $620M-$620M from $605M-$615M. Backs FY26 capital expenditures view $160M-$170M. Dalton added, "This success is most clearly reflected in our bookings which were spread across solutions and verticals, with notable strength in the TPA market where we closed several seven-figure transactions. With more than $70 million in bookings through the first half of 2026, we are well on our way to achieving our full year target of $100 million which would represent 50% growth over 2025 and is a leading indicator of continued growth in 2027 and beyond."

Justice Department Expands Antitrust Investigation into Claritev

The Justice Department is expanding an antitrust investigation into Claritev over allegations the company helped insurers, including UnitedHealth (UNH), CVS Health's (CVS) Aetna and Cigna (CI), illegally coordinate to reduce out-of-network reimbursement rates, Josh Sisco, Leah Nylen and Ike Swetlitz of Bloomberg report, citing people with knowledge of the matter. The Justice Department recently sent civil investigative demands to lawyers for a group of hospitals and doctor groups suing Claritev for alleged antitrust violations, sources told Bloomberg. The antitrust division is seeking information the providers are collecting during the litigation, people told the news agency. The Justice Department's inquiry involves similar allegations as the private litigation, the sources added. Shares of Claritev are down 10% to $26.92 following the report.